Drug Risk Assessment Needs IoM Report To Synthesize Research – CERTs
Executive Summary
The Institute of Medicine should study the current state of pharmaceutical risk assessment and recommend methodological and research improvements, participants in a Centers for Education & Research on Therapeutics risk assessment workshop suggested
You may also be interested in...
IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV
FDA's decision to proceed with an Institute of Medicine review of drug safety regulation could trigger a full-fledged debate over the possibility of creating a separate post-marketing regulatory agency in the U.S
IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV
FDA's decision to proceed with an Institute of Medicine review of drug safety regulation could trigger a full-fledged debate over the possibility of creating a separate post-marketing regulatory agency in the U.S
Rx Risk Descriptions Need To Be Standardized, FDA’s Galson Tells CERTs
The standardization of risk expressions to compare drugs would be a desirable risk management tool, Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, suggested at a recent CERTs meeting